The quality of the ligand density (especially before its inclusion in the model) together with the high values for the refined occupancies and the increase in refinement R factors when the ligand occupancy was set to zero provided convincing evidence that cyanopindolol is bound in the crystal and that the structure does not represent a ligand-free state. A ligand-bound state would be consistent with the very high affinity of cyanopindolol for β 1 -AR (13 pM) 6 . Only an experiment using radiolabeled cyanopindolol ligand was assigned an initial occupancy of 0.8 in both subunits. The resulting model (Supplementary Data Set 1) yielded R work and R free values of 34.4% and 38.2%, with a bond-length r.m.s. deviation of 0.013 Å, and the cyanopindolol occupancies refined to 1.00 for chain A and 0.84 for chain B. The electron density was well defined for the ligand in both chains (Fig. 1) . Fixing the occupancy of cyanopindolol to zero and repeating this refinement yielded substantially higher R work and R free values of 35.2% and 38.9%.
To the Editor:
Huang et al. 1 have reported a crystal structure of a thermostabilized avian β 1 -adrenergic receptor (β 1 -AR) that was described as being in a ligand-free basal state. Upon inspection of the electron density maps provided by the electron density server (http://eds.bmc.uu.se/) for the corresponding Protein Data Bank entry (PDB 4GPO), we observed substantial unmodeled electron density in the ligand-binding pocket. Given this unexpected result, the unusual distribution of atomic temperature factors in the deposited coordinates and the very high affinity of the cyanopindolol (which was used in the receptor preparation) for the b 1 -AR, we repeated the structure determination (Supplementary Data Sets 1 and 2), using the deposited structure factors.
We solved the structure by molecular replacement with PHASER 2 , using the structure of cyanopindolol-bound thermostabilized avian β 1 -AR(m23) (ref. 3; chain B of PDB 2VT4) after removal of all ligands, detergent molecules and waters. We used this model rather than the structure of the salbutamol-bound form (PDB 2Y04) chosen by Huang et al. because it was determined at higher resolution (2.7 Å for PDB 2VT4 versus 3.05 Å for PDB 2Y04). We selected chain B because it is the most complete model and does not display the kinked helix 1 found in chains A and C. PHASER produced a clear solution with two molecules in the crystallographic asymmetric unit, and we refined this model with REFMAC5 (ref. 4) , applying automatic noncrystallographic-symmetry restraints and restraining the model to a highresolution (2.1-Å) structure of β 1 -AR(m23) (PDB 4BVN) with PROSMART 5 . The resulting electron density map displayed good density for cyanopindolol in both subunits, although the density was stronger in chain A (Fig. 1) . We added cyanopindolol to the model and carried out another round of refinement without the PROSMART restraints but with the jelly-body restraints in REFMAC5. In this refinement, the Ligand occupancy in crystal structure of β 1 -adrenergic G protein-coupled receptor than the anisotropically truncated and sharpened data that were deposited; however the original data were not made available to us. The R factors for our final model are within the expected range for a structure refined at this resolution. A consequence of the presence of cyanopindolol in the PDB 4GPO crystal structure is that the dimensions of the ligand-binding pocket need to be reassessed. Specifically, the contraction of the ligand-binding pocket reported by Huang et al. is no longer feasible, owing to steric clashes between the ligand and the side chains on helix 5. The ligand-binding pocket in the structure that we have refined from the same data exhibits dimensions identical to those in the original cyanopindolol-bound structure (PDB 2VT4).
C O R R E S P O N D E N C E
The discrepancies that we have described in the PDB 4GPO structure are in the ligandbinding pocket. However, the interesting packing of β 1 -AR monomers within the crystal to form parallel dimers, which could be of physiological relevance, was unaffected upon rerefinement of the data. cyanopindolol bound to purified β 1 -AR to directly monitor ligand removal by dialysis, performed on the sample used to create the crystals, could have provided convincing evidence that all the cyanopindolol was actually removed and was therefore absent in the crystals produced.
The R factors that we report are markedly higher than those reported by Huang et al.
(R work 30.99% and R free 35.46%). There are two possible explanations for this: the first is differences in modeling the solvent contribution in PHENIX 7 and REFMAC5; the second is the unusual distribution of atomic B factors in the PDB 4GPO coordinate file, in which there are large differences in B factors for bonded side chain atoms, including B factors both increasing and decreasing along the length of the side chain (e.g., Met36 in chain A has B factors of 75, 30, 24, 118 and 128 Å 2 for CA, CB, CG, SD and CE atoms, respectively). This variation does not seem to be physically reasonable and may represent overfitting of the data. It would have been useful to carry out refinement against the original data rather
Huang et al. reply:
In response to the points raised by Leslie, Warne and Tate 1 , we reexamined the structural model that we deposited in the Protein Data Bank (PDB 4GPO) and obtained similar results to those that we reported previously 2 ; i.e., we could observe some small extra density but no ligands. In addition, we asked another protein crystallography group to check the deposited data set, and they were also unable to find ligands in our structure (Jean Jakoncic (Brookhaven National Laboratory), personal communication).
We then checked the electron density maps of our structure with other web servers. On the PDB_REDO web server, the maps from both the 'conservatively optimized structure' and the 'fully optimized structure' did not show extra density for a ligand in either chain A or chain B (http://www.cmbi.ru.nl/pdb_redo/gp/4gpo/ index.html). However, on the Electron Density Server (EDS), the map showed the presence of extra electron density in both chains. We do not know why the map on the EDS web server shows the presence of this extra density.
The presence or absence of cyanopindolol in our structural model was carefully discussed in the paper. From our radioligand binding studies, the β 1 -adrenergic receptor (β 1 -AR) protein sample used for the crystallization study yielded the same K d value for dihydroalprenolol as that in cells expressing wild-type β 1 -ARs. This indicated that most β1-ARs in the protein sample were not bound with cyanopindolol; otherwise, we would have observed a rightward shift in the competition curve. In addition, at pH 4, the ligand binding was decreased by approximately ten-fold compared to that at pH 7.7. From our mass spectrometry analysis, we estimated that, if cyanopindolol were present, <1% of receptors would be bound with cyanopindolol. One could argue that only cyanopindolol-bound β1-ARs were stable; however, in our hands, purified β1-AR(m23) proteins were stable at pH 4 for up to 6 months.
